AGEN:NSC-Agenus Inc. (USD)

EQUITY | Biotechnology | NASDAQ Capital Market

Last Closing

USD 3.66

Change

-0.18 (-4.69)%

Market Cap

USD 0.41B

Volume

0.58M

Analyst Target

USD 8.00
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Agenus Inc along with its subsidiaries is an immuno-oncology company. The Company is engaged in iscovery and development of revolutionary new treatments that engage the body's immune system to benefit patients suffering from cancer.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-05-21 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
VRTX Vertex Pharmaceuticals Inc

-1.29 (-0.30%)

USD 128.84B
REGN Regeneron Pharmaceuticals Inc

-7.77 (-1.29%)

USD 65.38B
ARGX argenx NV ADR

-3.51 (-0.60%)

USD 34.54B
ALNY Alnylam Pharmaceuticals Inc

-3.58 (-1.22%)

USD 32.75B
SMMT Summit Therapeutics PLC

+0.36 (+1.42%)

USD 27.07B
ONC BeiGene, Ltd.

+2.27 (+0.96%)

USD 26.35B
RPRX Royalty Pharma Plc

-0.52 (-1.58%)

USD 18.40B
INSM Insmed Inc

+0.14 (+0.21%)

USD 11.84B
INCY Incyte Corporation

-0.27 (-0.42%)

USD 11.42B
BMRN Biomarin Pharmaceutical Inc

-0.47 (-0.80%)

USD 11.29B

ETFs Containing AGEN

USPY:LSE L&G Cyber Security UCITS .. 4.96 % 0.00 %

-0.08 (0.19%)

USD 2.50B
ISPY:LSE L&G Cyber Security UCITS .. 4.89 % 0.00 %

+6.00 (+0.19%)

USD 2.50B
BUG Global X Cybersecurity ET.. 4.80 % 0.00 %

+0.60 (+0.19%)

USD 0.99B
FPXE First Trust IPOX Europe E.. 4.69 % 0.00 %

+0.01 (+0.19%)

USD 4.36M
FPXI First Trust International.. 4.09 % 0.70 %

-0.10 (0.19%)

USD 0.14B
CIBR:LSE First Trust Nasdaq Cybers.. 4.07 % 0.00 %

+0.08 (+0.19%)

USD 1.00B
FCBR:LSE First Trust Nasdaq Cybers.. 4.07 % 0.00 %

+6.25 (+0.19%)

USD 1.00B
CIBR First Trust NASDAQ Cybers.. 3.98 % 0.00 %

+0.86 (+0.19%)

USD 8.07B
ZLU-U:CA BMO Low Volatility US Equ.. 1.90 % 0.00 %

-0.29 (0.19%)

N/A
ZLU:CA BMO Low Volatility US Equ.. 1.90 % 0.33 %

-0.36 (0.19%)

CAD 2.16B

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange (NASDAQ Capital Market)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 33.58% 90% A- 91% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 33.58% 90% A- 91% A-
Trailing 12 Months  
Capital Gain -69.27% 28% F 11% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -69.27% 28% F 11% F
Trailing 5 Years  
Capital Gain -92.68% 33% F 10% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -92.68% 33% F 10% F
Average Annual (5 Year Horizon)  
Capital Gain 43.90% 78% C+ 88% B+
Dividend Return 43.90% 78% C+ 88% B+
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 478.36% 15% F 6% D-
Risk Adjusted Return 9.18% 62% D 45% F
Market Capitalization 0.41B 44% F 34% F

Key Financial Ratios

  Ratio vs. Industry/Classification (Biotechnology) Ratio vs. Market (NASDAQ Capital Market)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 0.46 77% 94%
Price/Book Ratio 218.61 2% 1%
Price / Cash Flow Ratio -0.43 22% 58%
Price/Free Cash Flow Ratio -2.43 65% 79%
Management Effectiveness  
Return on Equity -1,278.83% 5% 3%
Return on Invested Capital 54.68% 92% 95%
Return on Assets -28.79% 57% 19%
Debt to Equity Ratio -9.34% 79% 88%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Underpriced compared to earnings

The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector